Monday, July 17, 2017 2:12:47 PM
“This is the first prospective, randomized clinical trial to address the question of bevacizumab continuation in recurrent glioblastoma,” Dr. Hovey said. “Continuing bevacizumab after progression of recurrent glioblastoma did not improve PFS,” nor did it confer “any apparent clinical benefit.” She said that these results must be placed in context with a variety of other data, but this study suggests that bevacizumab should not routinely be continued beyond disease progression.
Discussant Timothy Cloughesy, MD, of the University of California, Los Angeles, called the data compelling. “We have been evaluating bevacizumab for 10 years, and we don’t have a really clear idea of where we’re going,” he said.
https://am.asco.org/no-benefit-continued-bevacizumab-recurrent-glioblastoma
Also, it looks like avastin achieved some crazy results in early trials that drove the FDA approval. Its median OS of 9.2 months in one phase 2 but subsequent trials have shown mOS to be in the range of 8 months (32 weeks).
Several phase I/II studies reported high responses and improved 6-month progression-free survival with Bevacizumab. Based on these results Bevacizumab, a vascular endothelial growth factor inhibitor received FDA approval for use in recurrent gliomas. Subsequently, a better planned randomized phase 2 BRAIN trial investigated bevacizumab alone and in combination with irinotecan did not show a convincing benefit of Bevacizumab compared with historical series [42]. The trial randomly allocated 167 patients with first or second relapse to receive Bevacizumab monotherapy or in combination with Irinotecan. The primary end points were 6-months PFS and overall response rate. The trial reported 6 months PFS 42.6% and 50.3% in the monotherapy and combination arm, and ORR 28.2% and 37.8% respectively. Median Overall survival was 9.2 months and 8.7 months respectively.
http://www.sciencedirect.com/science/article/pii/S111003621630036X
If VB-111 comes close to its phase 2 results (59 weeks mOS) then it would be an amazing accomplishment.
Recent VBLT News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/19/2024 08:56:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/12/2024 12:44:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/11/2024 09:00:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 09:20:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2024 04:15:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2024 01:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 01:15:22 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/16/2024 02:00:13 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/05/2024 10:00:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:05:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:04:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:04:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:02:17 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/11/2024 10:22:04 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 01/08/2024 09:21:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:00:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 10:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 01:15:18 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/29/2023 10:15:27 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM